Published in J Cardiovasc Electrophysiol on July 25, 2008
Efficacy Study of Sodium Channel Blocker in LQT3 Patients | NCT01648205
Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol (2013) 2.30
Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm (2011) 2.02
Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels. Am J Physiol Heart Circ Physiol (2010) 1.66
Importance of Knowing the Genotype and the Specific Mutation When Managing Patients with Long QT Syndrome. Circ Arrhythm Electrophysiol (2008) 1.48
Cardiac sodium channelopathies. Pflugers Arch (2009) 1.44
Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation (2011) 1.41
Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res (2012) 1.39
Use-dependent block of cardiac late Na(+) current by ranolazine. Heart Rhythm (2009) 1.23
Molecular and genetic basis of sudden cardiac death. J Clin Invest (2013) 1.23
Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol (2011) 1.08
Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening. Circ Res (2013) 1.04
Genetics of sudden cardiac death syndromes. Curr Opin Cardiol (2011) 1.02
Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects. J Physiol (2013) 1.02
Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction. Am J Cardiol (2011) 1.02
Genotype- and phenotype-guided management of congenital long QT syndrome. Curr Probl Cardiol (2013) 1.01
Recent progress in congenital long QT syndrome. Curr Opin Cardiol (2010) 0.99
Pathophysiology of the cardiac late Na current and its potential as a drug target. J Mol Cell Cardiol (2011) 0.95
The role of late I Na in development of cardiac arrhythmias. Handb Exp Pharmacol (2014) 0.93
Modulation of the late sodium current by ATX-II and ranolazine affects the reverse use-dependence and proarrhythmic liability of IKr blockade. Br J Pharmacol (2011) 0.92
Role of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death. Circ Res (2015) 0.91
Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine. J Mol Cell Cardiol (2009) 0.90
CrossTalk proposal: The late sodium current is an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction). J Physiol (2014) 0.90
CrossTalk opposing view: the late sodium current is not an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction). J Physiol (2014) 0.87
The investigation of sudden arrhythmic death syndrome (SADS)-the current approach to family screening and the future role of genomics and stem cell technology. Front Physiol (2013) 0.86
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol (2016) 0.86
Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics. Europace (2013) 0.85
Reduced Penetrance and Variable Expression of SCN5A Mutations and the Importance of Co-inherited Genetic Variants: Case Report and Review of the Literature. Indian Pacing Electrophysiol J (2014) 0.85
Molecular Pathophysiology of Congenital Long QT Syndrome. Physiol Rev (2017) 0.85
In silico assessment of drug safety in human heart applied to late sodium current blockers. Channels (Austin) (2014) 0.81
Inherited long QT syndrome: clinical manifestation, genetic diagnostics, and therapy. Herzschrittmacherther Elektrophysiol (2012) 0.81
Further Insights in the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction Defect. J Am Heart Assoc (2016) 0.81
Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study. Circulation (2016) 0.80
Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillation. Circ Arrhythm Electrophysiol (2013) 0.80
Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons. Br J Pharmacol (2013) 0.80
Emerging clinical role of ranolazine in the management of angina. Ther Clin Risk Manag (2010) 0.79
Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine. Front Pharmacol (2013) 0.78
Carbon monoxide effects on human ventricle action potential assessed by mathematical simulations. Front Physiol (2013) 0.78
18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels. Acta Pharmacol Sin (2012) 0.78
Stable angina pectoris: antianginal therapies and future directions. Nat Rev Cardiol (2011) 0.77
New treatment options for late Na current, arrhythmias, and diastolic dysfunction. Curr Heart Fail Rep (2012) 0.77
Genetics of inherited primary arrhythmia disorders. Appl Clin Genet (2015) 0.77
Use of ranolazine in long-QT syndrome type 3. J Cardiovasc Electrophysiol (2008) 0.77
[Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies]. Herzschrittmacherther Elektrophysiol (2015) 0.76
Genotype-phenotype correlation in long QT syndrome. Glob Cardiol Sci Pract (2015) 0.76
Multiple arrhythmic syndromes in a newborn, owing to a novel mutation in SCN5A. Can J Physiol Pharmacol (2011) 0.75
Channelopathies - emerging trends in the management of inherited arrhythmias. Indian Pacing Electrophysiol J (2015) 0.75
Personalized medicine to treat arrhythmias. Curr Opin Pharmacol (2013) 0.75
Long QT Syndrome: How Effective Therapy in a Single Patient Favorably Influenced the Long-Term Clinical Course and Genetic Understanding of this Hereditary Disorder. Prog Cardiovasc Dis (2015) 0.75
Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data. Circ Arrhythm Electrophysiol (2016) 0.75
Update on ranolazine in the management of angina. Vasc Health Risk Manag (2014) 0.75
Rebuttal from Marc Pourrier, Sarah Williams, Donald McAfee, Luiz Belardinelli and David Fedida. J Physiol (2014) 0.75
Monogenec Arrhythmic Syndromes: From Molecular and Genetic Aspects to Bedside. Acta Naturae (2016) 0.75
Complexity of ranolazine and phenytoin use in an infant with long QT syndrome type 3. HeartRhythm Case Rep (2016) 0.75
A case of long QT syndrome: challenges on a bumpy road. Clin Case Rep (2017) 0.75
[Genetic testing in hereditary arrythmia syndromes today and in the future]. Herzschrittmacherther Elektrophysiol (2012) 0.75
Ranolazine: safe and effective in a patient with hypertensive cardiomyopathy and multiple episodes of electrical storm. Clin Case Rep (2017) 0.75
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Molecular mechanism for an inherited cardiac arrhythmia. Nature (1995) 6.09
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation (2004) 4.13
The long QT syndrome. Prospective longitudinal study of 328 families. Circulation (1991) 3.99
Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther (2006) 2.21
Sequential versus simultaneous biventricular resynchronization for severe heart failure: evaluation by tissue Doppler imaging. Circulation (2002) 2.16
Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol (2004) 1.94
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther (2004) 1.88
Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation (2007) 1.82
Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol (2006) 1.70
Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther (2004) 1.66
Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. Ann Noninvasive Electrocardiol (2001) 1.33
Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol (2005) 1.31
Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol (2004) 1.17
Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. Circ Res (1999) 1.12
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71
Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol (2008) 4.63
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation (2004) 3.78
Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol (2008) 3.73
Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol (2003) 3.05
Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation (2004) 3.03
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol Psychiatry (2008) 2.91
Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation (2007) 2.88
Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol (2011) 2.84
Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82
Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). J Am Coll Cardiol (2013) 2.68
Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol (2009) 2.65
Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63
Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol (2005) 2.62
Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation (2011) 2.56
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation (2010) 2.49
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 2.41
The influence of public reporting of outcome data on medical decision making by physicians. Arch Intern Med (2005) 2.40
Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40
Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol (2006) 2.32
Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol (2012) 2.31
ALE Meta-Analysis Workflows Via the Brainmap Database: Progress Towards A Probabilistic Functional Brain Atlas. Front Neuroinform (2009) 2.29
Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation (2011) 2.26
Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol (2012) 2.26
Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol (2003) 2.22
Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation (2002) 2.20
Cardiovascular effects associated with air pollution: potential mechanisms and methods of testing. Inhal Toxicol (2002) 2.19
ECGScan: a method for conversion of paper electrocardiographic printouts to digital electrocardiographic files. J Electrocardiol (2005) 2.17
Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol (2011) 2.15
Mechanisms of ventricular fibrillation initiation in MADIT II patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol (2008) 2.13
Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA (2006) 2.12
Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation (2011) 2.08
Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Am Coll Cardiol (2013) 2.05
Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol (2005) 2.03
Usefulness of precordial T-wave inversion to distinguish arrhythmogenic right ventricular cardiomyopathy from idiopathic ventricular tachycardia arising from the right ventricular outflow tract. Am J Cardiol (2010) 2.02
Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc Electrophysiol (2010) 1.99
Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol (2011) 1.95
Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation (2012) 1.89
QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol (2006) 1.89
Clinical course and risk stratification of patients affected with the Jervell and Lange-Nielsen syndrome. J Cardiovasc Electrophysiol (2006) 1.88
Heart rate turbulence: standards of measurement, physiological interpretation, and clinical use: International Society for Holter and Noninvasive Electrophysiology Consensus. J Am Coll Cardiol (2008) 1.86
Gender differences and risk of ventricular tachycardia or ventricular fibrillation. Heart Rhythm (2008) 1.84
Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol (2009) 1.83
Comparison of the disparity between Talairach and MNI coordinates in functional neuroimaging data: validation of the Lancaster transform. Neuroimage (2010) 1.82
Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol (2009) 1.81
The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). J Am Coll Cardiol (2013) 1.79
Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels. Arterioscler Thromb Vasc Biol (2010) 1.79
Venous thrombosis and stenosis after implantation of pacemakers and defibrillators. J Interv Card Electrophysiol (2005) 1.79
Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol (2005) 1.78
Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II. Circulation (2006) 1.75
Reduction of the risk of recurring heart failure events with cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). J Am Coll Cardiol (2011) 1.74